TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04604223
Drug: Pioglitazone 45 mg
Normalized name: pioglitazone 45 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
Study: NCT04856371
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
Study: NCT04856371
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
Study: NCT04856371
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
Study: NCT05527340
Drug: Iberdomide
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO)
Study: NCT05527340
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40 mg (PO) (or 20 mg (PO) if patient ≥ 75 years old) should be administered on the days 1, 8, 15 and 22 of every 4-week cycle.
Study: NCT05527340
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days).
Study: NCT04937673
Drug: Camrelizumab+Albumin bound paclitaxel+Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks.
Study: NCT04937673
Drug: Camrelizumab+ Paclitaxel+ Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks.
Study: NCT04866225
Drug: Oral PF-06865571
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PF-06865571
Study: NCT05673889
Drug: ARV-471
Normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT05673889
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probe substrate
Study: NCT05320575
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.
Study: NCT06113809
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab
Study: NCT06113809
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)
Study: NCT06626737
Drug: Dapagliflozin (DAPA)
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will take Dapagliflozin 10mg every day in -1 to 14 days
Study: NCT05032950
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam administered as a single dose on Day 1
Study: NCT05032950
Drug: PF-07321332/ritonavir + Midazolam
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5
Study: NCT05032950
Drug: Ritonavir + Midazolam
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5
Study: NCT04193930
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet letrozole 2,5 mg/twice daily for 5 days
Study: NCT05032820
Drug: Lenalidomide and bb2121
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m2 and fludarabine 30mg/m2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x106 cells. Maintenance lenalidomide, starting at 10mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.
Study: NCT05479058
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Administered orally once daily
Study: NCT05485064
Drug: remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle
Study: NCT05922306
Drug: PEGylated recombinant human interferon alpha-2b injection
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.
Study: NCT05922306
Drug: PEGylated recombinant human interferon alpha-2b injection
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.
Study: NCT04193930
Drug: Menotropins
Normalized name: menotropins
DrugBank: Menotropins (DB00032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU of highly purified menotropins intramuscular
Study: NCT04193930
Drug: recombinant Follicular stimulating hormone
Normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: recombinant Follicular stimulating hormone 300- 400 IU
Study: NCT04965740
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational Cannabis
Study: NCT05751356
Drug: TR128
Normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TR128 will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Starting dose is 100mg, with escalation to 500mg.
Study: NCT06500247
Drug: Dalpicilib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with dalpicilib until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study: NCT06500247
Drug: Abiraterone Acetate (II)
Normalized name: Abiraterone Acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with Abiraterone Acetate (II) until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study: NCT06500247
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Prednisone until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study: NCT00035139
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04880616
Drug: NBI-827104
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT06012812
Drug: SHR-1819 injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1819 injection 300 mg Q2W
Study: NCT06172322
Drug: NTQ1062 with Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment).~Drug: Fulvestrant Injection 500mg in a 28-day cycle.
Study: NCT04870333
Drug: Niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
Study: NCT04870333
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be prescribed ciclesonide once daily, administered as follows:~Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
Study: NCT04870333
Drug: Sotrovimab
Normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: There will be a single infusion of sotrovimab administered at the beginning of the study.~500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter. Four vials will be required for a 2000 mg dose.
Study: NCT06373991
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of fludarabine.
Study: NCT06320067
Drug: Niraparib and Abiraterone Acetate Dual Action Tablet DAT
Normalized name: niraparib and abiraterone
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination product containing Niraparib (PARP inhibitor) and Abiraterone Acetate (ARSI). The regular-strength dual-action tablet (DAT) contains 100 mg niraparib/500mg AA per tablet. Patients take 2 tablets a day and receive a of total dose 200 mg niraparib/1000 mg AA. A low-strength DAT tablet containing 50 mg niraparib/500 mg AA may be available for participants requiring a dose reduction of niraparib.
Study: NCT06320067
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone Acetate is an ARSI. Single agent Abiraterone Acetate may be used in patients randomised to receive Niraparib and Abiraterone Acetate.
Study: NCT06320067
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apalutamide is an ARSI administered as a 240mg oral dose (four tablets taken together at the same time every day) with or without food. It is given daily in 28-day cycles.
Study: NCT06320067
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.
Study: NCT06056752
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fludarabine on days-5\~-2,the infusion dose is adjusted according to the subject's condition
Study: NCT06233695
Drug: Potassium sparing diuretic
Normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting Spironolactone or Eplerenone at the time of enrollment.
Study: NCT06559553
Drug: Selinexor+pegaspargase+dexamethasone
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
Study: NCT00257478
Drug: YM155
Normalized name: Sepantronium bromide
DrugBank: Sepantronium (DB17062)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05303636
Drug: LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LF111 (drospirenone 4 mg tablet orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28) or drospirenone (DRSP) 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (USA only). Subjects in the USA who choose to use the hormonal contraceptive method may choose between LF111 and DRSP 3.5 mg chewable tablets. The DRSP 3.5 mg chewable tablets are not available to subjects in Europe. Subjects in Europe who choose to use the hormonal contraceptive method will only receive LF111.
Study: NCT06082102
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib Tablets
Study: NCT06082102
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide Capsules
Study: NCT06082102
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab Injection
Study: NCT06082102
Drug: Orelabrutinib Placebo
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib Placebo Tablets
Study: NCT05866055
Drug: VX-973
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.
Study: NCT05866055
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Syrup for oral administration.
Study: NCT05535998
Drug: PD-1 inhibitors
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitors were intravenously administered on the first post-TACE day as follows: camrelizumab 200 mg or sintilimab 200 mg or toripalimab 240 mg or tislelizumab 200 mg, every 3-4 weeks.
Study: NCT04789434
Drug: PD-1 Inhibitor Tislelizumab maintenance therapy
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 Inhibitor Tislelizumab maintenance therapy, 200mg, every 2 months, 12 times
Study: NCT06194877
Drug: BGB-3245
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06194877
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous (IV) infusion via an infusion pump
Study: NCT00081640
Drug: PRO 2000/5 Gel (P)
DrugBank: PRO 2000 (DB05385)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05077449
Drug: XZP-3287+Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
Study: NCT05077449
Drug: Placebo + Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
Study: NCT05272813
Drug: MS-553
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-553
Study: NCT00433095
Drug: Navelbine
Normalized name: Navelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00433095
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00433095
Drug: Navelbine (oraly)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05510141
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard procedure
Study: NCT04682405
Drug: Uproleselan
Normalized name: Uproleselan
DrugBank: Uproleselan (DB14829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided by study
Study: NCT04682405
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Standard of care
Study: NCT05881187
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical application of riboflavin followed by cross linking
Study: NCT06641908
Drug: M3554
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B).
Study: NCT04640129
Drug: PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
Study: NCT04640129
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDF monotherapy
Study: NCT05325515
Drug: Conventional alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional alendronate 70mg weekly
Study: NCT06021145
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 26-week use of automated insulin delivery system with empagliflozin (2.5 mg daily) in individuals with suboptimal time in range.
Study: NCT00954460
Drug: velaglucerase alfa
Normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: up to 60 U/kg, every other week via intravenous infusion
Study: NCT06056115
Drug: Tislelizumab,Platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Induction therapy stage:~   Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~2. Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy .
Study: NCT05658146
Drug: Mavacamten Capsule 1
Normalized name: mavacamten Oral Capsule
DrugBank: AVAC (DB05441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05658146
Drug: Mavacamten Capsule 2
Normalized name: mavacamten Oral Capsule
DrugBank: AVAC (DB05441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05658146
Drug: Mavacamten Capsule 3
Normalized name: mavacamten Oral Capsule
DrugBank: AVAC (DB05441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days